Skip to Main Content

Rise and shine, everyone, another busy day is on the way. And so far, this is a quieter day than expected. The local water company, such as it is, has been drilling in the vicinity of the usually serene Pharmalot campus, but perhaps this is their day off. We will find out soon enough. Meanwhile, time for a cup of stimulation and some tidbits. As always, we wish you a smashing day and hope you will remember to pass along interesting secrets …

Cigna will become the latest payer to strike a deal with drug makers to receive discounts if certain medicines don’t help patients as expected, the Wall Street Journal writes. The insurer will get extra price discounts from Amgen, Regeneron Pharmaceuticals, and Sanofi for their pricey, new cholesterol medications known as PCSK9 inhibitors, which can greatly lower the LDL, or bad cholesterol, but cost roughly $14,000 a year.


A majority of Americans oppose federal regulatory changes to speed up the development and approval of new drugs and devices, according to a new poll from STAT and the Harvard T.H. Chan School of Public Health. The findings suggest the public has serious doubts about the 21st Century Cures legislation moving through Congress. Lawmakers from both parties want to change regulatory standards they blame for slowing the approval process for products.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.